Prevalence of chronic rhinosinusitis in the general population based on sinus radiology and symptomatology

Abstract

Background: The prevalence of chronic rhinosinusitis (CRS) measured in epidemiologic studies is 5% to 12%. This might be an overestimation because of overlap with other diseases, such as allergic rhinitis. Objective: We aimed to calculate the prevalence of CRS using a combination of epidemiologically based CRS according to the European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS) together with sinonasal opacification on imaging. Methods: Subjects who underwent a computed tomographic or magnetic resonance imaging scan of the head for any nonrhinologic indication were asked to fill in the Global Allergy and Asthma European Network survey containing EPOS symptom criteria. The scans were evaluated according to the Lund-Mackay (LM) scoring system. Epidemiologically based CRS is based on nasal symptoms according to EPOS; clinically based CRS also encompasses endoscopy and/or CT scanning. Results: Eight hundred thirty-four subjects were included. One hundred seven (12.8%) had epidemiologically based CRS according to EPOS. Of these subjects, 50% had an LM score of 0, 26% had an LM score of 1 to 3, and 23% had an LM score of 4 or greater. Twenty-five (3.0%) subjects had clinically based CRS (based on LM score > _4), and 53 (6.4%) subjects had clinically based CRS (based on LM score >0). Allergic rhinitis was reported by 167 (20%) subjects. In subjects who did not report upper airway symptoms, 57% had an LM score of 0, 30% had an LM score of 1 to 3, and 12% had an LM score of 4 or greater. Conclusion: We found a prevalence of 3.0% to 6.4% of clinically based CRS (depending on an LM cutoff point; ie, LM > _ 4 or LM > 0, respectively) in a relatively randomly selected group of subjects.

Tight junctions in the development of asthma, chronic rhinosinusitis, atopic dermatitis, eosinophilic esophagitis, and inflammatory bowel diseases

“…Innate and adaptive immunity is known to contribute to the heterogeneity of CRS 65 . The prevalence of clinically based CRS is 3.0% to 6.4% 66 . CRS is classified into CRS with or without polyps, and CRS with nasal polyps affects around 10% of the population 67 .…”

EUFOREA consensus on biologics for CRSwNP with or without asthma

“…5 Recently, the prevalence of clinically based CRS has shown to be between 3% and 6.4%. 6,7 CRS is classically divided into a phenotype with and without nasal polyps (CRSwNP and CRSsNP, respectively). Using patient questionnaires to measure the prevalence of CRSwNP yielded estimates of 2.1% (France) to 4.3% (Finland) in Europe and 1.1% in China.…”

Role of IL‐25, IL‐33, and TSLP in triggering united airway diseases toward type 2 inflammation

“…Uncontrolled moderate‐to‐severe AR is detrimental to asthma management, which is considered to be an independent risk factor for asthma 4‐6 . Chronic rhinosinusitis (CRS) is another highly prevalent chronic airway disease worldwide, varying from 5% to 12%, and the coincidence of asthma in CRS patients is more than twice for those without CRS 7 . As for asthma, the prevalence is also center‐specific, ranging from 5.2% to 16.8%.…”